|

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

RECRUITINGPhase 1Sponsored by USWM CT, LLC
Actively Recruiting
PhasePhase 1
SponsorUSWM CT, LLC
Started2018-04-09
Est. completion2032-04-01
Eligibility
Healthy vol.Accepted
Locations13 sites
View on ClinicalTrials.gov →

NCT03391778

Summary

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Participants who have received at least one dose of ADP adoptive cell therapy agent.
* Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
* Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* The investigator is responsible for review of medical history.
* Capable of giving signed informed consent.

Exclusion Criteria:

\- None

Conditions2

CancerNeoplasms

Interventions1

ADP adoptive cell therapy

Locations13 sites

Emory University School of Medicine
Atlanta, Georgia, 30322
Clinical Trials Call Center
ADP Investigational Site
Baltimore, Maryland, 21201
Clinical Trial Inquiries
National Cancer Institute - Center for Cancer Research
Bethesda, Maryland, 20892
University of Michigan
Ann Arbor, Michigan, 48109
Clinical Trial Inquiries
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110
Clinical Trial Inquiries

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.